Taylor Securities Services Inc. Buys New Shares in Amgen Inc. $AMGN

Taylor Securities Services Inc. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,625 shares of the medical research company’s stock, valued at approximately $859,000. Amgen comprises about 0.4% of Taylor Securities Services Inc.’s investment portfolio, making the stock its 23rd largest holding.

A number of other hedge funds have also recently bought and sold shares of the stock. Dogwood Wealth Management LLC lifted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the last quarter. Anfield Capital Management LLC grew its position in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund acquired a new position in shares of Amgen during the 4th quarter worth about $26,000. Manning & Napier Advisors LLC raised its holdings in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new stake in shares of Amgen in the 4th quarter valued at about $33,000. 76.50% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent analyst reports. Argus dropped their price objective on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Jefferies Financial Group assumed coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. The Goldman Sachs Group set a $389.00 price target on Amgen in a research note on Friday, June 5th. Finally, Morgan Stanley lifted their price objective on shares of Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $354.42.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $337.60 on Friday. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The business has a 50 day moving average of $340.71 and a 200-day moving average of $345.76. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The stock has a market cap of $182.21 billion, a PE ratio of 23.49, a P/E/G ratio of 3.39 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.